There are 511 resources available
4MO - Is it time for a new staging system for colon adenocarcinoma (CA)?
Presenter: N. Arvind Dasari
Session: Mini Oral session 1
Resources:
Abstract
6MO - Evaluation of plasma assessed comprehensive genomic profiling before first-line treatment with FOLFIRI plus cetuximab in RAS/BRAFV600E wild type metastatic colorectal cancer patients in the CAPRI 2-GOIM trial
Presenter: Giulia Martini
Session: Mini Oral session 1
Resources:
Abstract
5MO - Individual patient data (IPD) meta-analysis of randomised phase III trials (RP3) of chemotherapy for resectable colorectal cancer liver metastases (CRCLM): EORTC RP-2145
Presenter: Giacomo Bregni
Session: Mini Oral session 1
Resources:
Abstract
504MO - Phase I study of the PKMYT1 inhibitor lunresertib (lunre) in combination with FOLFIRI in advanced gastrointestinal (GI) cancers (MINOTAUR study)
Presenter: Elisa Fontana
Session: Mini Oral session 1
Resources:
Abstract
165MO - Early detection of HCC by routine blood based-AI
Presenter: Kin Nam Kwok
Session: Mini Oral session 1
Resources:
Abstract
211MO - First-line efficacy of [177Lu]Lu-DOTA-TATE in patients with advanced grade 2 and grade 3, well-differentiated gastroenteropancreatic neuroendocrine tumors by tumor grade and primary origin: Subgroup analysis of the phase III NETTER-2 study
Presenter: Simron Singh
Session: Mini Oral session 1
Resources:
Abstract
1O - Chemotherapy and liver transplantation versus chemotherapy alone in patients with definitively unresectable colorectal liver metastases: Updated results from the randomized TRANSMET trial
Presenter: Maximiliano Gelli
Session: Proffered Paper session
Resources:
Abstract
2O - Health-related quality of life (HRQoL) with first-line (1L) nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) in patients (pts) with microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC):
Presenter: Sara Lonardi
Session: Proffered Paper session
Resources:
Abstract
3O - PRODIGE 68 - UCGI 38 - SOREGATT: A randomized phase II study comparing the sequences of regorafenib (reg) and trifluridine/tipiracil (t/t) after failure of standard therapies in patients (pts) with metastatic colorectal cancer (mCRC)
Presenter: Michel Ducreux
Session: Proffered Paper session
Resources:
Abstract
LBA3 - Final analysis of the phase III KEYNOTE-585 study of pembrolizumab plus chemotherapy vs chemotherapy as perioperative therapy in locally-advanced gastric and gastroesophageal junction cancer
Presenter: Kohei Shitara
Session: Proffered Paper session
Resources:
Abstract